Effect in vitro and in vivo of a rat anti-CD2 monoclonal antibody (LO-CD2b) on pig to baboon xenogeneic cellular (T and natural killer cells) immune response

被引：0
|
作者：
Dehoux, JP [1 ]
de la Parra, B [1 ]
Latinne, D [1 ]
Bazin, H [1 ]
Gianello, P [1 ]
机构：
[1] Catholic Univ Louvain, B-3000 Louvain, Belgium
来源：
XENOTRANSPLANTATION | 2001年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
406
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [41] THERAPEUTIC EFFECTS OF A NOVEL FUSION OF ALT-803, AN IL-15 SUPERAGONIST, WITH 4 SINGLE-CHAINS OF ANTI-CD20 ANTIBODY (2B8T2M) IN COMBINATION WITH EXPANDED NATURAL KILLER CELLS AGAINST RITUXIMAB SENSITIVE AND RESISTANT BURKITT LYMPHOMA (BL)
    Chu, Y.
    Su, N.
    Alter, S.
    Jeng, E.
    Rhode, P.
    Barth, M.
    Lee, D.
    Wong, H. C.
    Cairo, M. S.
    CYTOTHERAPY, 2018, 20 (05) : S101 - S101
  • [42] 2B8T2M, a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 Antibody significantly enhanced expanded natural killer cells cytotoxicity against rituximab sensitive and resistant Burkitt lymphoma (BL)
    Chu, Yaya
    Su, Nang Kham
    Jeng, Emily K.
    Alter, Sarah
    Rhode, Peter R.
    Nayyar, Gaurav
    Barth, Mathew
    Lee, Dean A.
    Wong, Hing C.
    Cairo, Mitchell S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 46 - 47
  • [43] Therapeutic effects of 2B8T2M, a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 antibody in combination with expanded natural killer cells against rituximab sensitive and resistant Burkitt lymphoma (BL).
    Chu, Yaya
    Su, Nang Kham
    Alter, Sarah
    Jeng, Emily
    Rhode, Peter R.
    Barth, Matthew John
    Lee, Dean Anthony
    Wong, Hing C.
    Cairo, Mitchell S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [44] Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)
    Chu, Yaya
    Su, Nang Kham
    Alter, Sarah
    Jeng, Emily K.
    Rhode, Peter R.
    Barth, Matthew J.
    Lee, Dean Anthony
    Wong, Hing C.
    Cairo, Mitchell S.
    BLOOD, 2017, 130
  • [45] Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)
    Chu, Yaya
    Su, Nang Kham
    Alter, Sarah
    Jeng, Emily K.
    Rhode, Peter R.
    Barth, Matthew
    Lee, Dean
    Wong, Hing C.
    Cairo, Mitchell S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S75 - S76
  • [46] THERAPEUTIC EFFECTS OF A NOVEL FUSION OF ALT-803, AN IL-15 SUPERAGONIST, WITH 4 SINGLE-CHAINS of ANTI-CD20 ANTIBODY (2B8T2M) IN COMBINATION WITH EXPANDED NATURAL KILLER CELLS AGAINST RITUXIMAB SENSITIVE AND RESISTANT BURKITT LYMPHOMA (BL)
    Chu, Yaya
    Su, Nang Kham
    Alter, Sarah
    Jeng, Emily K.
    Rhode, Peter R.
    Barth, Mathew
    Lee, Dean A.
    Wong, Hing C.
    Cairo, Mitchell S.
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [47] Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
    Chen, Y.
    Xie, Y.
    Chan, T.
    Sami, A.
    Ahmed, S.
    Liu, Q.
    Xiang, J.
    CANCER GENE THERAPY, 2011, 18 (07) : 489 - 499
  • [48] Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
    Y Chen
    Y Xie
    T Chan
    A Sami
    S Ahmed
    Q Liu
    J Xiang
    Cancer Gene Therapy, 2011, 18 : 489 - 499
  • [49] Evaluation of the anti-tumor effects of an anti-Human Epidermal growth factor receptor 2 (HER2) monoclonal antibody in combination with CD11b+/Gr-1+myeloid cells depletion using a recombinant peptibody in 4 T1-HER2 tumor model
    Ramezani-Aliakbari, Khadijeh
    Khaki-Bakhtiarvand, Vahid
    Mahmoudian, Jafar
    Asgarian-Omran, Hossein
    Shokri, Fazel
    Hojjat-Farsangi, Mohammad
    Jeddi-Tehrani, Mahmood
    Shabani, Mahdi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 121
  • [50] NTB-A and 2B4 Natural Killer Cell Receptors Modulate the Capacity of a Cocktail of Non-Neutralizing Antibodies and a Small CD4-Mimetic to Eliminate HIV-1-Infected Cells by Antibody-Dependent Cellular Cytotoxicity
    Marchitto, Lorie
    Tauzin, Alexandra
    Benlarbi, Mehdi
    Beaudoin-Bussieres, Guillaume
    Dionne, Katrina
    Belanger, Etienne
    Chatterjee, Debashree
    Bourassa, Catherine
    Medjahed, Halima
    Yang, Derek
    Chiu, Ta-Jung
    Chen, Hung-Ching
    Smith III, Amos B.
    Richard, Jonathan
    Finzi, Andres
    VIRUSES-BASEL, 2024, 16 (07):
12345